2 active not recruiting, 2 recruiting, 2 unknown. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 2, Active not recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Active not recruiting 1 |
Follow XIANG YANQUN: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial TPC combined with Apatinib and Camrelizumab, GP Combined With Camrelizumab - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | XIANG YANQUN | 164 | 2024-05-30 | 2024-07-16 |
| Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy Irinotecan Liposomal combined With Nituzumab - Nasopharyngeal Cancer | Phase 2 | Active not recruiting | XIANG YANQUN | 38 | 2024-05-22 | 2024-12-30 |
| Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis. GP combined with Tislelizumab, TPC combined with Tislelizumab - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | XIANG YANQUN | 90 | 2024-05-15 | 2024-07-16 |
| Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma Capecitabine/Placebo combined with toripalimab - Nasopharyngeal Carcinoma, Maintenance Therapy | Phase 3 | Active not recruiting | XIANG YANQUN | 166 | 2023-04-28 | 2024-12-30 |
| PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma Toripalimab, Intensity modulated radiotherapy - Nasopharyngeal Carcinoma, T2-3N0 or T1-2N1 | Phase 2 | Unknown | XIANG YANQUN | 45 | 2022-03-12 | 2023-04-13 |
| Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab - Metastatic Nasopharyngeal Carcinoma, Chemotherapy Effect | Phase 2 | Unknown | XIANG YANQUN | 33 | 2021-07-29 | 2023-02-23 |
Nasopharyngeal Carcinoma (5) · Nasopharyngeal Neoplasms (1)
toripalimab (2) · Bevacizumab (1) · Capecitabine (1) · Radiotherapy, Intensity-Modulated (1) · apatinib (1) · camrelizumab (1) · sintilimab (1) · tislelizumab (1)
China (6)
Yanqun Xiang (1) · Yanqun Xiang, Dr (1) · Yanqun Xiang, Dr. (1)